Personalized digital health program for managing obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to develop a scalable and cost-effective digital health program tailored for individuals with pre-obesity and obesity. By integrating adaptive AI components, the program will provide personalized interventions to promote sustained behavioral changes and healthier lifestyle choices. Participants will be randomly assigned to different intervention groups, including self-health coaching using wearables, to assess the effectiveness of technology-driven support in improving health outcomes. The study will measure various health metrics, including physical activity, quality of life, and body composition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* obesity (BMI 27-42 kg/m²)
* capacity and willingness to use smartphone
* capacity and willingness to use wearables
* readiness to change (validated questionaire)

Exclusion Criteria:

* diseases that prevent participation in the program, or insufficiently controlled diseases, or terminal-stage illnesses
* excessive alcohol consumption or a history of other addictions
* patients currently participating in a weight-loss program (commercial, medically supervised, or a research study)
* patients using anti-obesity medications who are in the dosage adjustment phase within the last four weeks
* patients who are not mentally, physically, or technologically capable of participating
* patients who are unable to provide informed consent
* patients not adhering to the study protocol

Where it's running

• Center for Obesity Management EASO, Biomedical Research Center SAS
  Bratislava, Bratislava Region, Slovakia Recruiting

Study contacts

• Principal investigator: Jozef Ukropec, PhD, DSc — Biomedical Research Center Slovak Acad Sci
• Study coordinator: Barbara Ukropcová, Prof., MD, PhD
• Email: barbara.ukropcova@savba.sk
• Phone: 00421911643630

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.